Curriculum Vitae

Dr. med. Dr. nat. med. Deniz Hos, FEBO

 
 
 

Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50924 Cologne, GERMANY
Tel. (+49)-221-478 98896
Fax. (+49)-221-478 5094
Email: deniz.hos@uk-koeln.de

 
 
 

Scientific career

2002-2010 Medical School at the University of Erlangen-Nuremberg, Approbation (licence to practice medicine)

2006-2009 Study of Molecular Medicine at the University of Erlangen-Nuremberg, Diploma in Molecular Medicine

2006-2010 Doctorate degree (Dr. med) (summa cum laude) at the University of Erlangen-Nuremberg

2011- Resident physician and scientific assistant, Department of Ophthalmology, University Hospital of Cologne

2012-2016 PhD degree, Center for Molecular Medicine Cologne (CMMC), University of Cologne

2013- Management Committee Member, EU COST Action BM1302

2013-2015 GEROK research rotation, Medical Faculty, University of Cologne

2014- Speaker, Young DOG (Residents of the German Ophthalmological Society)

2015- Principal Investigator of Project 5 “Myeloid cell function in corneal hem- and lymphangiogenesis” in the DFG Research Unit FOR 2240 “Angiogenesis, Lymphangiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye” at the Department of Ophthalmology, University of Cologne

2016 European and German Board Exam in Ophthalmology

2017- Co-Principal Investigator, B3 “Novel therapeutic role of myeloid cell-derived VEGF-C and lymphangiogenesis in resolution of corneal inflammation and reestablishment of corneal transparency”, Center for Molecular Medicine Cologne (CMMC)

2018- Principal Investigator of Project 5 “Myeloid cell function in corneal hem- and lymphangiogenesis” in the DFG Research Unit FOR 2240 “Angiogenesis, Lymphangiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye” at the Department of Ophthalmology, University of Cologne

 
 
 

Prizes and honors

2007 Travel grant, GlaxoSmithKline GmbH, ARVO Annual Meeting 2007, Fort Lauderdale, USA

2007 Research scholarship of the Interdisciplinary Center of Clinical Research, IZKF, University of Erlangen-Nuremberg

2010 Karl Giehrl Award 2011 for best medical dissertation, University of Erlangen-Nuremberg

2013 Dry Eye Research Award, Annual Meeting of the German Ophthalmological Society (DOG) 2013, Berlin, Germany

2014 Research Award of the German Ophthalmological Society (Eye foundation)

2017 Nomination “European Leadership Development Programme”, Class 2017-2019, European Society of Ophthalmology

 
 
 

Selected publications

Cursiefen C, Bock F, Clahsen T, Regenfuss B, Reis A, Steven P, Heindl LM, Bosch JJ, Hos D, Eming S, Grajewski R, Heiligenhaus A, Fauser S, Austin J, Langmann T. [New Therapeutic Approaches in Inflammatory Diseases of the Eye – Targeting Lymphangiogenesis and Cellular Immunity: Research Unit FOR 2240 Presents Itself]. Klin Monbl Augenheilkd. 2017 May;234(5):679-685.

Hos D, Tuac O, Schaub F, Stanzel TP, Schrittenlocher S, Hellmich M, Bachmann  BO, Cursiefen C. Incidence and Clinical Course of Immune Reactions after Descemet Membrane Endothelial Keratoplasty: Retrospective Analysis of 1000 Consecutive Eyes. Ophthalmology. 2017 Apr;124(4):512-518.

Hos D, Bucher F, Regenfuss B, Dreisow ML, Bock F, Heindl LM, Eming SA, Cursiefen C. IL-10 Indirectly Regulates Corneal Lymphangiogenesis and Resolution of Inflammation via Macrophages. Am J Pathol. 2016;186:159-71.

Hos D, Dörrie J, Schaft N, Bock F, Notara M, Kruse FE, Krautwald S, Cursiefen C, Bachmann BO. Blockade of CCR7 leads to decreased dendritic cell migration to draining lymph nodes and promotes graft survival in low-risk corneal transplantation. Exp Eye Res. 2015 Dec;146:1-6. [Epub ahead of print]

Lee HS, Hos D, Blanco T, Bock F, Reyes NJ, Mathew R, Cursiefen C, Dana R, Saban DR. Involvement of corneal lymphangiogenesis in a mouse model of allergic eye disease. Invest Ophthalmol Vis Sci. 2015 May;56(5):3140-8

Hos D, Schlereth SL, Bock F, Heindl LM, Cursiefen C. Antilymphangiogenic therapy to promote transplant survival and to reduce cancer metastasis: what can we learn from the eye? Semin Cell Dev Biol. 2015 Feb;38:117-30

Hos D, Cursiefen C. Lymphatic vessels in the development of tissue and organ rejection. Adv Anat Embryol Cell Biol. 2014;214:119-41

Hos D, Koch KR, Bucher F, Bock F, Cursiefen C, Heindl LM. Serum eyedrops antagonize the anti(lymph)angiogenic effects of bevacizumab in vitro and in vivo. Invest Ophthalmol Vis Sci. 2013;54:6133-42.

Hos D, Regenfuss B, Bock F, Onderka J, Cursiefen C. Blockade of insulin receptor substrate-1 inhibits corneal lymphangiogenesis. Invest Ophthalmol Vis Sci. 2011;52:5778-85.

Hos D, Saban DR, Bock F, Regenfuss B, Onderka J, Masli S, Cursiefen C. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. Arch Ophthalmol. 2011; 129:445-52.

Hos D, Bock F, Dietrich T, Onderka J, Kruse FE, Thierauch KH, Cursiefen C. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest Ophthalmol Vis Sci. 2008;49:1836-42.

Hos D, Bachmann B, Bock F, Onderka J, Cursiefen C.Age-related changes in murine limbal lymphatic vessels and corneal lymphangiogenesis. Exp Eye Res. 2008;87:427-32.